This pan-Asian , 26-week trial investigated efficacy and safety of IDegAsp vs biphasic insulin aspart 30 ( BIAsp 30 ) in Asian adults with type 2 diabetes ( T2DM ) , inadequately controlled on once - or twice-daily ( BID ) basal , premixed or self-mixed insulin .